anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled external drug containing kallikrein. CONSTITUTION:An external drug for treating dermatopathy obtained by kneading kallikrein simply with a base, e.g. water-absorbing ointment, white ointment, hydrophilic ointment, simple ointment or hydrophilic vaseline, or if necessary dissolving the kallikrein in propylene glycol or polyethylene glycol (preferably 2- 10% based on the base), and kneading the resultant solution in the base. The content of the kallikrein therein is preferably 1-100g kallikrein units/g, particularly preferably 10-30g kallikrein units/g. The drug is effective particularly for dermatopathy, e.g. chaps, hand roughening, dermatitis, necrotic angiopathy, frostbite and bed sore. The kallikrein is widely used as a vasodilator, and regarded as effective for cerebral arteriosclerosis, hypertension and tissue trophopathy derived from hematogenic disorder. The kallikrein is wholly used in the form of tablet or injection, and there has been no external drug in the past.
An initial intravenous loading dose of Levothyroxine Sodium for Injection between 300 to 500 mcg, followed by once daily intravenous maintenance doses between 50 and 100 mcg, should be administered, as clinically indicated, until the patient can tolerate oral therapy. 

The age, general physical condition, cardiac risk factors, and clinical severity of myxedema and duration of myxedema symptoms should be considered when determining the starting and maintenance dosages of Levothyroxine Sodium for Injection. 

Levothyroxine Sodium for Injection produces a gradual increase in the circulating concentrations of the hormone with an approximate half-life of 9 to 10 days in hypothyroid patients. Daily administration of Levothyroxine Sodium for Injection should be maintained until the patient is capable of tolerating an oral dose and is clinically stable. For chronic treatment of hypothyroidism, an oral dosage form of levothyroxine should be used to maintain a euthyroid state. Relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Based on medical practice, the relative bioavailability between oral and intravenous administration of Levothyroxine Sodium for Injection is estimated to be from 48 to 74%. Due to differences in absorption characteristics of patients and the oral levothyroxine product formulations, TSH and thyroid hormone levels should be measured a few weeks after initiating oral levothyroxine and dose adjusted accordingly.
BACKGROUND: The impact of the distance from the root of splenic artery to tumor (DST) on the prognosis and optimal surgical procedures in the patients with pancreatic body/tail cancer has been unclear.
METHODS: We retrospectively analyzed 94 patients who underwent distal pancreatectomy (DP) and 17 patients who underwent DP with celiac axis resection (DP-CAR) between 2008 and 2018.
RESULTS: The 111 patients were assigned by DST length (in mm) as DST = 0: n = 14, 0<DST≤10: n = 18, and 10<DST: n = 79. The median overall survival (OS) and relapse-free survival (RFS) did not significantly differ in each group. A multivariate analysis showed that DST was not an independent prognostic factor for both RFS and OS. DP-CAR did not improve the prognosis in the DST = 0 and the 0<DST≤10 groups. In the DST = 0 group, neoadjuvant therapy significantly decreased distant metastasis (P = 0.025) and improve the overall survival (P = 0.046).
CONCLUSIONS: DST did not affect prognosis in patients with pancreatic body/tail cancer. Neoadjuvant therapy followed by DP may be desirable for patients with a DST = 0 tumor. For those with a 0<DST≤10 tumor, DP may be suitable; DP-CAR is an alternative when ligation and dissection of the root of the splenic artery are difficult or not possible.
The present invention concerns particles comprising a chitin component, such as chitosan or a derivative thereof, associated with a polynucleotide encoding an interferon (IFN) molecule, 2-5' oligoadenylate synthetase (2-5 AS), or a combination thereof. Preferably, the chitin component comprises chitosan or a derivative thereof. The particles of the invention are useful for delivery and expression of the interferon-encoding and/or 2-5 AS-encoding polynucleotide within a host in vitro or in vivo. The invention further concerns pharmaceutical compositions comprising particles of the invention and a pharmaceutically acceptable carrier, and a method for producing particles of the present invention. The present invention further pertains to a method of inducing apoptosis in a cancer cell, such as a lung cancer cell, by contacting a target cancer cell in vitro or in vivo with an effective amount of particles of the invention. In one embodiment, a therapeutically effective amount of particles are administered to target cancer cells within a patient in vivo, for treatment of cancer, such as lung cancer. The particles and therapeutic methods of the invention provide anti-metastatic and anti-cancer therapeutics for cancer patients, particularly lung cancer patients.
Cardiac fistulas present diagnostical and therapeutical challenges due to their variability in size, shape and pathway. Three-dimensional printing is increasingly used to provide a tactile representation that aids in preoperative planning and patient education. We present the case of a female in her 60s who developed a fistula between the left ventricle, right atrium and coronary sinus 2 years after bioprosthetic valve replacement. We used three-dimensional modelling to better understand her cardiac anatomy and optimise our surgical approach. She was discharged home without deficit following an uneventful postoperative course. Three-dimensional printing can improve patient care through tangible demonstration, preoperative planning and trainee education.
In developing countries, diarrheal diseases are a leading cause of childhood morbidity and mortality. In the United States an estimated 4.67 million children per year suffer from gastroenteritis with a diarrheal component, impacting the delivery and cost of healthcare. Seventy-five percent of these children are brought to physician care across a range of settings from clinics to emergency departments. Children less than five years of age average 1.3 - 2.5 episodes per year, with 1.4% of those children requiring hospitalization annually. This results in an estimated 209,000 hospitalizations yearly for gastroenteritis. The impact of acute gastrointestinal disease can be felt in the developed world, including the United States, as cost attributed to hospitalization and productivity lost. Attempts at treating gastroenteritis have included Oral Rehydration Solution (ORS), introduced 30 years ago by the WHO, which continues to provide a safe and effective way to maintain hydration during acute illness. ORS, however, does not reduce the volume or frequency of stool output in diarrhea. The anti-diarrheal medication loperamide (Imodium®) was commonly used in children until reports of serious adverse reactions caused its use to fall out of favor. There are no other medications or supplements available to specifically treat the diarrheal component of gastroenteritis and studies have shown that adherence to treatment recommendations regarding fluid therapy is poor because care givers want to reduce duration of illness as opposed to supporting children through the natural course of the disease. The desire to relieve diarrheal symptoms often leads care givers to seek antibiotics during a time of rising antibiotic resistance, as well as other treatments with no proven efficacy.

Zinc is an essential trace element for humans. Its physiologic roles are seen throughout the body as a critical cofactor for enzymatic reactions; most notable are its actions in the gastrointestinal (GI) tract. Zinc is an important component of brush border enzymatic activity which promotes gastrointestinal absorption, it regulates water/electrolyte transport at the cellular level, and it enhances the repair of the intestinal mucosa by bolstering immune function. Over the past 10-15 years, there have been more than a dozen randomized controlled trials of zinc supplementation performed in children living in developing countries that have reported improvements in the duration and severity of diarrhea when compared to placebo in a variety of in- and outpatient settings. The majority of zinc trials were conducted in countries at high risk of zinc deficiency, but those conducted at medium risk showed similar effect on duration and severity. When stratified across all nutritional groups based on serum zinc levels a significant effect was seen compared to placebo despite baseline zinc level, with no occurrence of serious adverse reaction in any group. Given these results, the WHO has endorsed zinc supplementation for all children with acute diarrhea, despite the lack of data from similarly designed studies in industrialized/developed settings.
BACKGROUND/AIM: Regorafenib is an oral multikinase inhibitor used in later lines for metastatic colorectal carcinoma (mCRC) treatment, but its efficacy and tolerability are low. To improve the response rates and ameliorate adverse effects, different strategies have been implemented. In our study, we examined the effect of statin usage in patients with mCRC treated with regorafenib.
PATIENTS AND METHODS: This single-center retrospective study included patients with mCRC who were treated with regorafenib between January 2015 and December 2023. The primary outcomes were progression-free survival (PFS) and overall survival (OS), and the secondary outcomes were adverse effects and the tolerability of regorafenib.
RESULTS: The data of 105 patients were collected retrospectively. The median age of the patients was 66 years, and 60 patients were male. Seventeen patients (16.1%) were receiving statins. Statin-using patients were significantly older than non-users (72 years vs. 66.5 years, p=0.05). Comorbid diseases were more common in patients using statins. The median PFS was 1.9 months for statin users and 4.2 months for statin non-users (p<0.001), and the median OS was 4.7 vs. 6.7 months (p=0.01). Cox regression revealed that statin usage was significantly associated with a higher hazard ratio (HR) for PFS (2.53) and OS (2.06) (both p<0.01 and p=0.02, respectively).
CONCLUSION: Statins are associated with decreased survival and response rates in patients with mCRC treated with regorafenib. However, further studies are needed to confirm these results.
Duloxetine delayed-release capsules, USP are available as:

20 mg Size 4 gelatin capsule, opaque yellow cap/opaque yellow body hard gelatin capsule filled with white to grey pellets. The capsule is printed with “Y201” on cap and “20 mg” on body with green ink.

30 mg Size 3 gelatin capsule, opaque blue cap/opaque white body hard gelatin capsule filled with white to grey pellets. The capsule is printed with “Y202” on cap and “30 mg” on body with yellow ink.

60 mg Size 1 gelatin capsule, opaque blue cap/opaque yellow body hard gelatin capsule filled with white to grey pellets. The capsule is printed with “Y203” on cap and “60 mg” on body with white ink.
Patients with L1196 (including L1196M) mutation receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, or ensartinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After gastric bypass many patients suffer from early and/or late dumping syndrome as a reaction to carbohydrate rich meals. Gastric emptying after bypass is accelerated and nutrition enters the intestine faster, which leads to osmotically driven fluid shifts from the blood to the lumen. Late dumping occurs 1-3 h after eating, and is caused by hyperinsulinemia and is therefore characterized by symptoms of hypoglycemia like weakness, sweating, and dizziness. Many people have both types. In most studies examining satiety hormones after oral glucose stimulation in non-operated patients, glucose loads of 50-75g are used. For a measurable GLP-1 rise a threshold of 2 kcal/min. at the intestine is needed. After gastric bypass gastric emptying is accelerated and less glucose is necessary to reach this threshold. The "threshold load" and "tolerable load without dumping symptoms" is not yet know.
Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml \& 5ml syringes.
PURPOSE:To provide a specific antibody having a specified bonding activity to shrimp infectious disease pathogens used for passive immunity, and also to provide a shrink infectious disease control composition compounded with the antibody and effective for the control of the shrimp infectious diseases. CONSTITUTION:The specific antibody has a specified bonding activity to the pathogens of shrimp infectious diseases, e.g. bacterial pathogen such as vibrio bacteria or viral pathogen such as Baculoviridae. Preferably, an egg antibody or milk antibody obtained from the egg of a laying hen hyperimmunized with the above antibody or from the milk of a mammalian hyperimmunized with the antibody. And, the shrimp infectious diseases control composition, preferably a shrimp feed, is compounded with the antibody as an active ingredient for controlling the shrimp infectious diseases. The administration of the antibody or the composition compounded with the antibody into the shrimp permits to effectively control the shrimp infectious diseases, especially the shrimp viral infectious diseases having not had any controlling method as well as the shrimp bacterial infections diseases.
FIELD: cosmetology. SUBSTANCE: new compositions of diorganosiloxanes type with short linear or cyclic chain or triorganosiloxanes type with general characteristic which results in that they contain at least one benzotriazol link with acrylate or akrylamide function. Composition is primary used as organic sun filters in cosmetic compositions designed for skin and hair protection against ultraviolet radiation. For this purpose, composition is applied on skin or hair in effective content. EFFECT: improved solubility in fat substances; higher efficiency. 27 cl, 3 ex
In clinical trials, 5093 adult and adolescent patients (3841 U.S. and 1252 non-U.S.) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration.

In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N = 3841 cefdinir-treated patients):

The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with cefdinir, were seen during clinical trials conducted in the U.S.:
PURPOSE:To obtain a promoter for hepatic regeneration capable of increasing hepatic cells and promoting the regeneration of the liver. CONSTITUTION:The objective promoter for hepatic regeneration comprises alanine and/or glutamine in an effective amount as an essential ingredient. When a mixture of the alanine with the glutamine is used, the weight ratio thereof is preferably (1/0.1) to (1/10). In this case, they may be contained as a di- to a tripeptide. The daily dose for an adult is >=1g in the total amount of the amino acids. In order to ensure promoting effects on the hepatic regeneration, this promoter is preferably continuously administered at an interval of, e.g. 3hr or 6hr. Furthermore, since the amino acids are respectively approved as foods, there is no possibility of exhibiting toxicity, especially acute toxicity. The promoter for the hepatic regeneration has the effects and remarkable amelioration of hepatopathy can be expected, wide utilization such as a therapeutic agent for fulminant hepatitis, an ameliorant for viral hepatopathy, a therapeutic agent or a preventing agent for hepatopathy due to medicines such as anticancer agents or promotion of hepatic regeneration after the operation of the liver such as liver transplantation, induction of renal regeneration, etc.
INTRODUCTION: The indications for cementless short-stem total hip arthroplasty (THA) have been expanded due to encouraging results. However, no evidence in cases of femoral neck fractures (FNFs) is available. We aimed to prospectively obtain data on the safety and the clinical outcomes of a cementless calcar-guided short stem in patients with FNFs.
MATERIALS AND METHODS: We conducted a prospective observational study of 68 patients diagnosed with FNFs who underwent short-stem THA between 2016 and 2019 with a calcar-guided stem. Complications during follow-up leading to revision were documented, and patient reported outcome measurements recorded. Stem migration was analyzed using the Einzel-Bild-Röntgen-Analysis Femoral Component Analysis software.
RESULTS: The mean follow-up was 33.8 ± 14.8 months. The patient mortality at last follow-up was 10.6%. Two patients required stem revision, due to periprosthetic fracture and late aseptic loosening, respectively, corresponding to 96.2% stem survival. Survivorship for the endpoint of revision for any reason was 91.1% at 6 years. All revisions occurred in females. The mean Harris Hip Score at the last follow-up was 93.0 ± 8.9. The mean axial migration at last follow-up was 1.90 ± 1.81 mm. No significant influence on migration was found regarding gender, age, weight, and body mass index.
CONCLUSIONS: The clinical and radiological findings were satisfying and most patients benefited from the minimally invasive procedure. However, as for conventional THA as well, implant survivorship and mortality were markedly worse compared to results regarding osteoarthritis. Especially in elderly female patients with FNF, cementless short-stem THA is a concern and a cemented THA should be the first choice.
INTRODUCTION: The Symani surgical system undergoes scrutiny in this study as part of a series of preclinical investigations. Previous studies compared the precision of robotic-assisted anastomoses with manual techniques. This study aimed to evaluate the critical, histological, and gross parameters at the site of anastomosis and at distant sites in a rat model to provide insights into the safety and efficacy of robotic-assisted microsurgery to enhance its potential for clinical adoption.
MATERIALS AND METHODS: Experienced microsurgeons performed arterial and venous anastomoses in 16 Wistar rats, randomized into four treatment groups: robotic artery, robotic vein, manual artery, and manual vein. Various parameters were evaluated at two time points (T0 and T30) on the day of the procedure and at Day 28 (T28d). In the second phase of the study, the animals underwent necropsy, histopathologic analysis, micro-CT scans, and angiography imaging of the anastomosis sites, major organs, and distant target organs by a blinded assessor.
RESULTS: Patency rates were 100% at T0 and T30 for all anastomoses and stayed at 100% on T28d for the robotic subgroups; however, it decreased to 87.5% for manual arterial anastomoses owing to a case of obstructive thrombus. No evidence of clot migration was observed. Blood flow parameters and procedure times did not differ significantly. The blinded semiquantitative histological analysis revealed no significant disparities between the robotic and manual anastomoses across various pathological indicators. No gross abnormalities were detected in musculoskeletal examinations.
CONCLUSION: This preclinical study demonstrated the safety of the Symani surgical system. Results suggest equivalence between robotic and manual techniques regarding thrombus formation at the anastomotic site and distal organs.
BACKGROUND: Subarachnoid hemorrhage (SAH) represents a severe injury to the brain and is associated with a high mortality (40%). Several experimental SAH models are described in the literature requiring specialized equipment and a high degree of surgical expertise. Our goal was to validate a simplified, cost-effective model to permit future studies of SAH.
METHODS: SAH was induced by injection of homologous blood into the cisterna magna. Perfusion-fixation then perfusion of gelatinous India ink was performed. Brains and brainstems were collected and imaged for analysis of cerebral vasospasm. Triphenyl tetrazolium chloride (TTC) staining was used to analyze brain tissue cell death 24 hours following stroke. A composite neuroscore was utilized to assess SAH-related neurologic deficits.
RESULTS: Anterior cerebral artery and basilary artery diameters were significantly reduced at 24 hours post SAH induction. Middle cerebral artery diameter was also reduced; however, the results were not significant. TTC staining showed no infarcted tissue. Neuroscores were significantly lower in the SAH mice, indicating the presence of functional deficits.
CONCLUSIONS: This simplified model of SAH elicits pathological changes consistent with those described for more complex models in the literature. Therefore, it can be used in future preclinical studies examining the pathophysiology of SAH and novel treatment options.
Adult mammals are known for their poor ability to regenerate tissues, including tendons. On the other hand, urodeles have become an important model in regenerative studies for their remarkable ability to regenerate various body parts and organs throughout life, such as limbs, retinas, or even the brain. However, little is known about their capacity to regenerate injured tendons. If newts can also repair tendons without scar formation, they may be a suitable animal model for tendon regeneration studies in other adult vertebrates. Therefore, the present study used Iberian ribbed newts to characterize mechanical and structural regeneration of tendons following transection, using tensile tests and multiphoton microscopy. A digital flexor tendon in a hindlimb was transected either partially or completely, and regenerated tendon was examined 6 and 12 weeks after the operation. Tensile strength of regenerated tendons was significantly less than normal at 6 weeks, but was remarkably recovered at 12 weeks, reaching levels comparable to those of uninjured tendons. On the other hand, mouse tendons demonstrated poor recovery of strength even after 12 weeks. Multiphoton microscopy revealed that tendon-like collagenous tissue bridges residual tendon stubs in newts, but disorganized scar-like tissue filled the injured location in mice. These findings highlight the remarkable capacity of newts to recover from tendon injury and confirm the utility of newts as a model to study tendon regeneration.
The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick.